Validea Detailed Fundamental Analysis

Validea's Multi-Factor Investor model, based on Pim van Vliet's low-volatility strategy, assigned ELEVANCE HEALTH INC (ELV) a 68% rating. While ELV passed market capitalization and standard deviation criteria, it received 'NEUTRAL' for momentum and net payout yield, resulting in a 'FAIL' for its final rank within this specific strategy. This rating falls below the 80% threshold for 'some interest' and 90% for 'strong interest', indicating ELV is not a strong fit for this particular low-volatility, high-momentum, high-payout yield investment approach.

Analysis

Elevance Health Inc. (ELV) received a suboptimal rating of 68% from Validea's Multi-Factor Investor model, which is based on Pim van Vliet's strategy prioritizing low volatility, strong momentum, and high net payout yield. This score falls short of the 80% threshold considered necessary to indicate strategic interest. While ELV passes the model's criteria for large market capitalization and low standard deviation, aligning with the low-risk component of the strategy, its overall assessment resulted in a 'FAIL'. The primary detractors were its 'NEUTRAL' ratings on 'Twelve Minus One Momentum' and 'Net Payout Yield'. This indicates that, despite its favorable low-volatility profile, ELV currently lacks the requisite performance momentum and shareholder return characteristics to qualify as a top candidate under this specific quantitative framework.

Key Decisions for Investors

• Investors employing factor-based strategies similar to Pim van Vliet's should note that ELV fails to meet the combined criteria for low-risk, high-momentum, and high-yield, making it an unsuitable candidate for such models at present.
• For investors focused purely on a low-volatility mandate, ELV's 'PASS' on standard deviation is a positive signal, but the neutral momentum and yield metrics warrant further investigation to understand the drivers of its recent performance and capital allocation policy.
• Traders and portfolio managers should monitor for any catalysts that could improve ELV's momentum or prompt an increase in its net payout yield, as such changes could significantly alter its rating within quantitative screens and attract factor-driven capital.